BrandonEdwardKremerMDPhD

Physician

Dr. Kremer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
16 Penn Tower
3400 Spruce Street
Philadelphia, PA 19104
Phone+1 215-662-5858

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2011 - 2016
University of Pennsylvania Health SystemResidency, Internal Medicine, 2009 - 2011
University of Virginia School of MedicineClass of 2009

PubMed

DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma.
Kazutaka Sunami, Shinsuke Iida, Nobuhiro Tsukada, Taku Fujii, Hitomi Kato
International Journal of Hematology. 2025-02-01
13 citations
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Meletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, Sosana Delimpasi, Vladimir Vorobyev
The New England Journal of Medicine. 2024-08-01
1 citations
Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms.
Justin Watts, Mark D Minden, Kimo Bachiashvili, Andrew M Brunner, Sameem Abedin
Therapeutic Advances in Hematology. 2024-01-01

Abstracts/Posters

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...
Brandon E Kremer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Sin...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018